GNI Group Ltd. (TYO:2160)

Market Cap	144.78B
Revenue (ttm)	24.13B
Net Income (ttm)	-147.00M
Shares Out	55.56M
EPS (ttm)	-2.93
PE Ratio	n/a
Forward PE	19.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	884,600
Average Volume	1,365,155
Open	2,632.00
Previous Close	2,653.00
Day's Range	2,575.00 - 2,642.00
52-Week Range	1,469.00 - 4,410.00
Beta	1.14
RSI	38.06
Earnings Date	Aug 14, 2025

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in deve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 867
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 2160

Financial Performance

In 2024, GNI Group's revenue was 23.61 billion, a decrease of -9.22% compared to the previous year's 26.01 billion. Earnings were 1.10 billion, a decrease of -86.43%.